CN114502537A - 突变型idh2抑制剂及其应用 - Google Patents

突变型idh2抑制剂及其应用 Download PDF

Info

Publication number
CN114502537A
CN114502537A CN202080066252.8A CN202080066252A CN114502537A CN 114502537 A CN114502537 A CN 114502537A CN 202080066252 A CN202080066252 A CN 202080066252A CN 114502537 A CN114502537 A CN 114502537A
Authority
CN
China
Prior art keywords
pyridin
trifluoromethyl
triazin
amine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080066252.8A
Other languages
English (en)
Inventor
徐晓峰
王超
马腾
容红飞
丁列明
王家炳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CN114502537A publication Critical patent/CN114502537A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一种作为突变型异柠檬酸脱氢酶2(IDH2)抑制剂的化合物(如式I所示)及其制备方法、药物组合物。还涉及上述化合物或其药物组合物在治疗突变型IDH2介导的疾病中的用途。IDH2抑制剂能够抑制携带最常见IDH2突变体的细胞中2‑HG的生成，是一种低毒性作用且高效靶向抗肿瘤药物的理想靶标。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080066252.8A 2019-09-29 2020-09-27 突变型idh2抑制剂及其应用 Pending CN114502537A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019109302156 2019-09-29
CN201910930215 2019-09-29
PCT/CN2020/118127 WO2021057975A1 (zh) 2019-09-29 2020-09-27 突变型idh2抑制剂及其应用

Publications (1)

Publication Number Publication Date
CN114502537A true CN114502537A (zh) 2022-05-13

Family

ID=75165590

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080066252.8A Pending CN114502537A (zh) 2019-09-29 2020-09-27 突变型idh2抑制剂及其应用

Country Status (3)

Country Link
CN (1) CN114502537A (zh)
TW (1) TW202126637A (zh)
WO (1) WO2021057975A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563258A (zh) * 2021-07-29 2021-10-29 派普医药(江苏)有限公司 一种4-溴-2-(二氟甲基)-5-甲基吡啶的制备方法
CN113502276B (zh) * 2021-08-03 2022-07-15 昆明理工大学 异柠檬酸脱氢酶在提高植物甲醛吸收代谢能力中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
WO2013102431A1 (en) * 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016177347A1 (en) * 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
WO2018014852A1 (zh) * 2016-07-21 2018-01-25 南京圣和药业股份有限公司 作为异柠檬酸脱氢酶抑制剂的化合物及其应用
CN110051673A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 一种包含三嗪类idh抑制剂的药物组合物及其用途
CN110054614A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 三嗪类idh抑制剂的可药用盐及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
WO2013102431A1 (en) * 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016177347A1 (en) * 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
WO2018014852A1 (zh) * 2016-07-21 2018-01-25 南京圣和药业股份有限公司 作为异柠檬酸脱氢酶抑制剂的化合物及其应用
CN110051673A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 一种包含三嗪类idh抑制剂的药物组合物及其用途
CN110054614A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 三嗪类idh抑制剂的可药用盐及其制备方法

Also Published As

Publication number Publication date
WO2021057975A1 (zh) 2021-04-01
TW202126637A (zh) 2021-07-16

Similar Documents

Publication Publication Date Title
EP2857404B1 (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
JP2022518860A (ja) 免疫調節剤、組成物およびその使用方法
CN113748114B (zh) 一种喹唑啉化合物及其在医药上的应用
TWI609866B (zh) 新穎吡唑衍生物
WO2018017983A1 (en) Compounds useful for treating disorders related to ret
EP1943243B1 (en) Kinase inhibitors
CN109422755A (zh) 一种含氮杂环化合物、制备方法、中间体、组合物和应用
CN111499634B (zh) 一种喹唑啉化合物及其在医药上的应用
CN107141293A (zh) 一种含氮杂环化合物、制备方法、中间体、组合物和应用
BR112016011024B1 (pt) Composto, composição farmacêutica, e, usos dos mesmos
WO2005063738A1 (ja) 新規２－へテロアリール置換ベンズイミダゾール誘導体
AU2018320418B2 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
EP3247705B1 (en) Quinazoline and quinoline compounds and uses thereof as nampt inhibitors
WO2021057975A1 (zh) 突变型idh2抑制剂及其应用
CN112851668A (zh) Atr抑制剂及其在医药上的应用
CN112204024B (zh) Erk抑制剂及其应用
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CN111051309A (zh) 可用作a2a受体拮抗剂的三唑并三嗪衍生物
TW202140446A (zh) 喹啉基膦氧化合物及其組合物和用途
CN111164084A (zh) 可用作a2a受体拮抗剂的三唑并三嗪衍生物
CN113423398A (zh) Mek抑制剂及其在医药上的应用
KR20180098285A (ko) 페닐이미다졸 화합물
KR20230000462A (ko) Ron 억제제로서의 신규한 피리딘 유도체 화합물
CN115141202A (zh) 嘧啶并吡嗪酮化合物及其用途
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination